Anti-Phospho-CPI-17 (Thr38) mAb

  • Applications
    • ELISA
    • WB
  • Target CPI-17
  • Host Species Mouse
  • Species Reactivities Human, Mouse, Rat
  • Code # CY-M1024
  • Size 100 μg
  • Price
    $401.02
Specifications

Background

Myosin phosphatase (MLCP) plays a critical regulatory role in the Ca(2+) sensitivity of myosin phosphorylation and smooth muscle contraction. It has been suggested that phosphorylation at Thr696 of the MLCP regulatory subunit (MBS/MYPT1) and at Thr38 of the CPI-17, which is MLCP inhibitor protein, results in inhibition of MLCP activity. The phosphorylation of CPI-17 Thr38 is thought to play an important role in G-protein-mediated inhibition of MLCP in tonic arterial smooth muscle. The CPI-17 phosphorylation transiently increased after agonist stimulation in both alpha-toxin skinned and intact fibers. The time course of the increase in CPI-17 phosphorylation after stimulation correlated with the increase in myosin regulatory light chain (MLC20) phosphorylation. These results strongly suggest that the phosphorylation of CPI-17 plays a significant role in the agonist-induced increase in myosin phosphorylation and contraction of smooth muscle in the Ca(2+)-independent activation mechanism of smooth muscle contraction. This anti-Phospho-CPI-17 Thr38 monoclonal antibody has been validated with PKC, however it has the potential for use in evaluating other serine threonine kinases such as Rho-Kinase, protein kinase N and ILK.
  • Antibody Type:
    Monoclonal
  • Application:
    ELISA, WB
  • Clone Number:
    AK-1F11
  • Concentration:
    1.0 mg/mL
  • Conjugate:
    Unlabeled
  • Description:

    Monoclonal Antibody of 100 μg targeting CPI-17 for ELISA, WB.

  • Formulation:
    Supplied in 20mM phosphatase buffer (pH 7.5), 300mM NaCl, 50% glycerol.
  • Host Species:
    Mouse
  • Immunogen:
    Near the Thr38 phosphorylated peptide synthesis of human CPI-17 (binding KLH)
  • Isotype:
    IgG1
  • Product Type:
    Antibody
  • Reactivity:
    Phospho-CPI-17 Thr38 Antibody detects phosphorylated recombinant CPI-17 whenphosphorylated at threonine38 in vitro. The antibody doesnot recognize the unphosphorylated CPI-17 protein. Theantibody detects the 17 kDa phospho-CPI-17 by Westernblotting a
  • Research Area:
    Cell Biology
  • Short Description:

    Anti-Phospho-CPI-17 (Thr38) Monoclonal Antibody.

  • Size:
    100 μg
  • Species Reactivity:
    Human, Mouse, Rat
  • Storage Temperature:
    -20°C
  • Target:
    CPI-17
References
  1. Hirano K, et al. Protein kinase network in the regulation of phosphorylation and dephosphorylation of smooth muscle myosin light chain. Mol. Cell Biochem. 248:105-14 (2003).
  2. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol. 522:177-85 (2000).
  3. Niiro N, et al. Agonist-induced changes in the phosphorylation of the myosin-binding subunit of myosin light chain phosphatase and CPI17, two regulatory factors of myosin light chain phosphatase, in smooth muscle. Biochem J. 369:117-28 (2003).
  4. Kitazawa T, et al. Phosphorylation of the myosin phosphatase targeting subunit and CPI-17 during Ca2+ sensitization in rabbit smooth muscle. J. Physiol. 546:879-89 (2003).
  5. Kitazawa T, et al. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J. Biol. Chem. 275:9897-900 (2000)
  6. Woodsome TP, et al. Expression of CPI-17 and myosin phosphatase correlates with Ca(2+) sensitivity of protein kinase C-induced contraction in rabbit smooth muscle. J. Physiol. 535:553-64 (2001).
  7. Deng JT, et al. Phosphorylation of the myosin phosphatase inhibitors, CPI-17 and PHI-1, by integrin-linked kinase. Biochem J. 367:517-24 (2002)
  8. Li L, et al. Possible involvement of the novel CPI-17 protein in protein kinase C signal transduction of rabbit arterial smooth muscle. J. Physiol. 508:871-81 (1998).
  9. Kitazawa T, et al. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J. Biol. Chem. 275: 9897-900 (2000)